Oncotelic Therapeutics Past Earnings Performance
Past criteria checks 0/6
Oncotelic Therapeutics has been growing earnings at an average annual rate of 12.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 56.6% per year.
Key information
12.2%
Earnings growth rate
47.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -56.6% |
| Return on equity | -60.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Oncotelic Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -5 | 0 | 0 |
| 30 Jun 24 | 0 | -1 | 0 | 0 |
| 31 Mar 24 | 0 | -8 | 1 | 0 |
| 31 Dec 23 | 0 | -8 | 1 | 0 |
| 30 Sep 23 | 0 | -12 | 1 | 0 |
| 30 Jun 23 | 0 | -13 | 1 | 0 |
| 31 Mar 23 | 0 | 9 | 1 | 0 |
| 31 Dec 22 | 0 | 5 | 5 | 1 |
| 30 Sep 22 | 0 | 9 | 5 | 1 |
| 30 Jun 22 | 0 | 8 | 6 | 2 |
| 31 Mar 22 | 0 | -11 | 9 | 3 |
| 31 Dec 21 | 0 | -9 | 5 | 4 |
| 30 Sep 21 | 0 | -11 | 5 | 6 |
| 30 Jun 21 | 0 | -11 | 5 | 6 |
| 31 Mar 21 | 1 | -8 | 3 | 6 |
| 31 Dec 20 | 2 | -10 | 5 | 4 |
| 30 Sep 20 | 2 | -10 | 5 | 2 |
| 30 Jun 20 | 2 | -9 | 5 | 1 |
| 31 Mar 20 | 0 | -10 | 5 | 1 |
| 31 Dec 19 | 0 | -7 | 3 | 1 |
| 30 Sep 19 | 0 | -3 | 2 | 1 |
| 30 Jun 19 | 0 | -3 | 1 | 1 |
| 31 Mar 19 | 0 | -2 | 1 | 1 |
| 31 Dec 18 | 0 | -1 | 0 | 1 |
Quality Earnings: OTLC is currently unprofitable.
Growing Profit Margin: OTLC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OTLC is unprofitable, but has reduced losses over the past 5 years at a rate of 12.2% per year.
Accelerating Growth: Unable to compare OTLC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OTLC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: OTLC has a negative Return on Equity (-60.45%), as it is currently unprofitable.